Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25843064 | 0.84 | ADRB1 (0.40) | — | |
| SCHEMBL25842997 | 0.83 | TYMS (0.36) | TYMS | |
| SCHEMBL25843066 | 0.81 | FBP1 (0.46) | — | |
| SCHEMBL25843121 | 0.79 | TYMS (0.44) | TYMS | |
| SCHEMBL146996 | 0.75 | P2RY2 (0.42) | TYMS | |
| SCHEMBL19412412 | 0.75 | P2RY2 (0.42) | TYMS | |
| SCHEMBL25842996 | 0.75 | FBP1 (0.47) | — | |
| SCHEMBL22765896 | 0.70 | TYMS (0.50) | TYMS | |
| SCHEMBL4321066 | 0.70 | TYMS (0.53) | TYMS | |
| SCHEMBL22990560 | 0.69 | POLB (0.62) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219994-A1 | MODIFIED NUCLEOSIDE AND SYNTHESIS METHOD THEREFOR | Stemirna Therapeutics Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219994-A1 | MODIFIED NUCLEOSIDE AND SYNTHESIS METHOD THEREFOR | RNMT, RNGTT, BCDIN3D | TYMS 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.